GeneDx Holdings Corp. $WGS Shares Acquired by Principal Financial Group Inc.

Principal Financial Group Inc. increased its stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 25.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 102,929 shares of the company’s stock after acquiring an additional 20,966 shares during the period. Principal Financial Group Inc.’s holdings in GeneDx were worth $6,610,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Westfield Capital Management Co. LP boosted its position in GeneDx by 87.1% in the 4th quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock worth $132,435,000 after purchasing an additional 474,167 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of GeneDx by 60.4% in the 4th quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock valued at $142,154,000 after purchasing an additional 411,607 shares during the period. Invesco Ltd. lifted its stake in shares of GeneDx by 59.2% in the 4th quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock valued at $102,288,000 after purchasing an additional 292,394 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of GeneDx by 65.9% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 633,457 shares of the company’s stock valued at $40,681,000 after purchasing an additional 251,732 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in GeneDx by 717.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 258,745 shares of the company’s stock worth $33,652,000 after buying an additional 227,088 shares in the last quarter. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

WGS has been the topic of a number of analyst reports. Zacks Research cut GeneDx from a “hold” rating to a “strong sell” rating in a research report on Monday, June 29th. Wall Street Zen cut GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $75.00 target price (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. TD Cowen reiterated a “buy” rating on shares of GeneDx in a research report on Wednesday, July 15th. Finally, BTIG Research dropped their price target on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Seven research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $87.43.

Insider Buying and Selling at GeneDx

In other news, Director Keith A. Meister acquired 533,758 shares of the firm’s stock in a transaction on Thursday, May 7th. The shares were bought at an average price of $37.86 per share, for a total transaction of $20,208,077.88. Following the acquisition, the director owned 3,761,908 shares of the company’s stock, valued at approximately $142,425,836.88. This trade represents a 16.53% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Casdin Capital, Llc purchased 185,000 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were acquired at an average price of $42.60 per share, for a total transaction of $7,881,000.00. Following the completion of the transaction, the director directly owned 3,367,164 shares of the company’s stock, valued at $143,441,186.40. The trade was a 5.81% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders purchased 2,256,420 shares of company stock valued at $93,144,340 and sold 21,699 shares valued at $1,295,646. 25.17% of the stock is currently owned by corporate insiders.

GeneDx News Summary

Here are the key news stories impacting GeneDx this week:

• Negative Sentiment: Several law firms reiterated that a securities class action has been filed against GeneDx and certain executives on behalf of investors who bought shares between April 16, 2025, and May 4, 2026. The complaints allege violations of U.S. securities laws and seek damages for investors; the allegations have not been proven. Securities class action announcement
• Negative Sentiment: The central allegations concern GeneDx’s acquisition of Fabric Genomics. Investors claim the company misrepresented the expected benefits and financial impact of the acquisition, while subsequent reassessment exposed a gap between acquisition promises and operating results. One notice associated the allegations with a roughly 49% decline in WGS shares during the relevant period. WGS shareholder alert
• Neutral Sentiment: The repeated notices from Bragar Eagel & Squire, Robbins LLP, Kahn Swick & Foti, Hagens Berman, Faruqi & Faruqi, DJS Law Group, Rosen Law Firm and Bronstein, Gewirtz & Grossman primarily encourage affected investors to contact counsel before the August 3 lead-plaintiff deadline. These announcements do not represent a new operating update or a final court determination. GeneDx class action deadline notice

GeneDx Price Performance

Shares of GeneDx stock opened at $60.54 on Tuesday. The stock has a market capitalization of $1.80 billion, a P/E ratio of -22.59 and a beta of 1.90. The business has a 50 day simple moving average of $59.11 and a two-hundred day simple moving average of $71.49. GeneDx Holdings Corp. has a 12 month low of $32.21 and a 12 month high of $170.87. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The firm had revenue of $102.25 million during the quarter, compared to analyst estimates of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same period in the prior year, the firm earned ($0.23) earnings per share. As a group, analysts predict that GeneDx Holdings Corp. will post -1 EPS for the current fiscal year.

GeneDx Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.